Perceptive Xontogeny Venture Fund Provides $40M Series A Financing to Forge Biologics

Choate represented Perceptive Xontogeny Venture Fund as the lead investor in a $40M Series A financing to Forge Biologics Holdings, LLC, a viral vector gene therapy manufacturing and development company with the dual platform of CDMO capabilities and the development of proprietary gene therapy products. The proceeds of this financing will be used to expand AAV manufacturing CDMO capabilities in 2020, with cGMP production capacity available by mid-2021, and for the development of a novel gene therapy pipeline.